Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports
$16,500.00   |  '

Primary Sclerosing Cholangitis | Executive Insights | US |2019

Login to access report north_east
Buy report north_east

MARKET OUTLOOK

Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colon cancer. The median age of diagnosis is 42 years, and it is more common in men than in women. Despite the severity of PSC, no therapies are approved to treat it. Current treatment with UDCA and fenofibrates offers some clinical benefit but does not prevent the progression to liver cirrhosis or cholangiocarcinoma. However, several therapies with novel mechanisms of action are in development to treat PSC and will be used first line if they prove safe and efficacious. These therapies will capitalize on the immense unmet need in this space.

QUESTIONS ANSWERED

  •  What are the key areas of unmet need and opportunity in the PSC therapy market?
  •  What is the prevalence of PSC in the United States?
  • How are PSC patients currently treated in the United States?
  •  What therapies are in development for PSC?
  •  How does each current and future player influence the market, and how will this scenario change in the future?
  •  What are the key drivers and limiters of the PSC therapy market?

CONTENT HIGHLIGHTS

  • Geography: United States
  • Primary Research: Three KOL interviews in December 2019
  • Key Companies Covered:  Cymabay, Gilead, Intercept Pharmaceuticals, Dr. Falk Pharma, High Tide Biopharma, Acorda Therapeutics, Immunic
  • Drugs Covered:  Seladelpar, cilofexor, norursodeoxycholic acid, Ocaliva, HTD 1801, timolumab, vidofludimus calcium

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east